Veru (NASDAQ:VERU – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Veru (NASDAQ:VERU – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $4.14 million for the quarter, compared to analyst estimates of $3.00 million. Veru had a negative return on equity of 130.13% and a negative net margin of 265.27%. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Veru Price Performance
Shares of NASDAQ:VERU opened at $0.86 on Friday. The business’s 50-day moving average is $0.92 and its 200-day moving average is $0.88. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The company has a market capitalization of $126.55 million, a price-to-earnings ratio of -2.65 and a beta of -0.44.
Insider Buying and Selling at Veru
Analyst Ratings Changes
Several analysts have recently commented on VERU shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Veru in a research report on Monday, May 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price target (down from $7.00) on shares of Veru in a research note on Monday, April 15th. Finally, B. Riley initiated coverage on Veru in a research note on Tuesday, May 14th. They issued a “buy” rating and a $5.00 target price for the company.
Check Out Our Latest Analysis on Veru
Veru Company Profile
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- How to Invest in Biotech Stocks
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
- How to Effectively Use the MarketBeat Ratings Screener
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
- How Can Investors Benefit From After-Hours Trading
- DraftKings Shares Fall After EPS Beat, Lower EBITDA Guidance
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.